本帖最后由 老马 于 2012-1-13 21:20 编辑 0 w, ?$ W0 g( a6 J0 w$ i# c4 F
. `2 Y4 B% I! ~; _# G: n8 g5 E; W
爱必妥和阿瓦斯丁的比较" o' p- B2 T4 {; H; k$ h
( n7 A0 J5 }4 }% @2 R- `
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
5 u1 l7 b! v$ S) _# @
$ E4 G o1 s5 R( c- Q* y9 e
- V: c ?1 z, ^5 P ]! L( y$ H
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
3 K* N5 i4 V# w# D9 ?9 h' M" ] H==================================================# c6 I: b+ V# F
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
* G! w; f7 L8 }) b1 M7 x- S* m' GPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.* S8 B, Q) G5 \5 i8 Q* Y- g
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
# C; @" u+ X; K6 R7 e8 u: D
|